About AnaptysBio
AnaptysBio is a publicly listed company based in San Diego (United States) founded in 2005. Immunology therapeutics are developed for cancer and inflammatory diseases. AnaptysBio has raised $85.23 million across 7 funding rounds from investors including Frazier Healthcare Partners, BVF Partners and BioMedPartners. The company has 136 employees. Its chief executive, as recorded, is Daniel Faga. Its website anaptysbio.com draws about 11 thousand monthly visits. AnaptysBio offers products and services including Rosnilimab, ANB033, ANB101, Jemperli, and TIM-3 Antagonist. Its focus areas include Life Sciences, Immunotherapy, Antibody and Immunomodulatory. Its legal entity is AnaptysBio, Inc. Its competitors include Moderna, Roivant Sciences and BeiGene; 3 of its 3 listed competitors have raised funding.
Company details
AnaptysBio was founded in 2005 in San Diego, United States, and operates in the biotechnology sector. Immunology therapeutics are developed by the company, focusing on immune cell modulators for autoimmune and inflammatory conditions, as well as cancer. Key programs include rosnilimab, a PD-1 agonist targeted at moderate-to-severe rheumatoid arthritis, and ANB032, a BTLA agonist for moderate-to-severe atopic dermatitis. Operations center on advancing these candidates through clinical development.
- Headquarters San Diego, United States
- Employees 136
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website anaptysbio.com
- Social LinkedIn X
- Legal Name Anaptysbio, Inc.
- Annual Revenue$234.6 M (USD)157.01as on Dec 31, 2025
- Net Profit-$13.23 M (USD)90.89as on Dec 31, 2025
- EBITDA$50.32 M (USD)as on Dec 31, 2025
- Total Equity Funding$85.23M (USD)
in 7 rounds
- Latest Funding Round$40.77M (USD), Series D
Jul 2015
- InvestorsFrazier Healthcare Partners
& 8 more
- Employee Count136
Products & Services of AnaptysBio
AnaptysBio offers a comprehensive portfolio of products and services, including Rosnilimab, ANB033, ANB101, Jemperli, and TIM-3 Antagonist.
Targets PD-1+ T cells for rheumatoid arthritis and ulcerative colitis treatment
CD122 antagonist in Phase 1 trials for inflammatory conditions
BDCA2 modulator entering Phase 1 trials for autoimmune disorders
PD-1 antagonist licensed to GSK for immuno-oncology applications
Antibody licensed to GSK for potential cancer immunotherapy
Funding Insights of AnaptysBio
AnaptysBio has successfully raised a total of $85.23M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $40.77 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $85.23M
- Total Rounds 7
- Last Round Series D — $40.77M
- First Round $500,000
(Jun 2007)
- Investors Count 9
All 7 funding rounds of AnaptysBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2015 | $40.77M | Series D | – | BVF Partners, BioMedPartners | – |
| Oct 2013 | $2.02M | Series B | – | – | – |
| Oct 2011 | $8.02M | Series B | – | – | – |
| Feb 2011 | $14,400 | Series B | – | – | – |
| Sep 2008 | $505,998 | Series B | – | – | – |
| Nov 2007 | $33.9M | Series B | – | – | |
| Jun 2007 | $500,000 | Debt – Convertible | – | – | – |
9 investors in total: 9 institutional.
Investors in AnaptysBio
AnaptysBio has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Frazier Healthcare Partners, BVF Partners and BioMedPartners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe | biomedvc.com | Basel, Switzerland | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Late-stage life sciences investments are managed via VC and PE. | hbmpartners.com | Zug, Switzerland | ||
Early stage venture capital firm investing in the US | alloyventures.com | Palo Alto, United States | ||
Seed and early-stage venture capital is provided to US companies. | avalon-ventures.com | Cambridge, United States | ||
Venture capital & advisory firm | numenorventures.com | Park City, United States | ||
| longwoodcapitaladvisors.com |
Investor details for AnaptysBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AnaptysBio
79 people are tracked at AnaptysBio (37 in leadership, 10 in board & advisors, 32 in team); the tracked headcount is 136.
| Name | Role | Group |
|---|---|---|
Daniel Faga | CEO | Leadership |
Jonathan Bernhard | Director Corporate Development | Leadership |
Eric Loumeau | Chief Legal Officer | Leadership |
Paul F. Lizzul | Chief Medical Officer | Leadership |
Hamza Suri | President & CEO | Leadership |
Nghi Nguyen | Vice President, Corporate Development | Leadership |
Joe Sheffer | Associate Director, Early Stage Development, CMC | Leadership |
Rosemary Cesario | Director, Pre-clinical Project Management | Leadership |
Laurence Altobell III | Associate Director, Protein Sciences | Leadership |
Catherine R. Aversa | Senior Director, Translational Research | Leadership |
Steve Toth | Executive Director, Regulatory Affairs | Leadership |
Ben Stone | Chief Business Officer | Leadership |
Paul Brewer | Associate Director | Leadership |
Dennis Mulroy | CFO | Leadership |
Alex Praseuth | Senior Director Drug Product And Formulation Development | Leadership |
Cory Okuna | Head Of Information Technology | Leadership |
Maria Padilla (Judy) | Associate Director Of Financial Reporting | Leadership |
Zurab MacHaidze | Senior Medical Director, Clinical Development. | Leadership |
Claire Cotton | Director, Accounting | Leadership |
Glenn Speirs | Sr. Director, Financial Planning And Analysis | Leadership |
59 more people are available in the full profile.
Complete people profiles for AnaptysBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of AnaptysBio
AnaptysBio is a publicly listed company on the NASDAQ with ticker symbol ANAB in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Jan 2017
- Listed onNASDAQ: ANAB
- Listed entityAnaptysBio, Inc.
- Exchange sectorHealth technology
Timeline of AnaptysBio
4 dated milestones of AnaptysBio across 12 years, from founding to its latest funding, stage changes and deals.
- Founded AnaptysBio is founded.
- Funding First funding round of $500K.
- Funding Latest funding round, Series D, of $40.8M.
- IPO Lists on the stock exchange (IPO).
Competitors of AnaptysBio
AnaptysBio has 3 listed competitors in our database, 3 of them funded. They include Moderna, Roivant Sciences and BeiGene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. |
Detailed competitors of AnaptysBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AnaptysBio
The website of AnaptysBio (anaptysbio.com) receives about 10.8K visits a month and ranks #1,418,623 among all websites worldwide, #1,841 in Biotechnology and Pharmaceuticals.
- Monthly visits10.8K
▼ 38.9% vs previous month
- Unique visitors6.3K
per month
- Global rank#1,418,623
among all websites
- Category rank#1,841
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit2.2
- Average visit38 sec
- DevicesDesktop 23% · Mobile 77%
Websites whose visitors overlap most with AnaptysBio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| linkp.com | 92% | 1.8K | #9,022,027 | View details | |
| agenusbio.com | 79% | 8.9K | #3,213,430 | View details |
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as AnaptysBio (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Anaptysbio
Complete news archive for AnaptysBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AnaptysBio
AnaptysBio was founded in 2005 and raised its 1st funding round 2 years after it was founded.
AnaptysBio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Daniel Faga is the CEO of AnaptysBio, as recorded in our data.
AnaptysBio is a funded company, having raised a total of $85.23M across 7 funding rounds to date. The company's 1st funding round was a Debt – Convertible of $500K, raised on Jun 2007.
AnaptysBio has 136 employees.
Annual revenue of AnaptysBio is $234.6M as on Dec 31, 2025.
AnaptysBio was founded in 2005 in San Diego, United States, and operates in the biotechnology sector. Immunology therapeutics are developed by the company, focusing on immune cell modulators for autoimmune and inflammatory conditions, as well as cancer. Key programs include rosnilimab, a PD-1 agonist targeted at moderate-to-severe rheumatoid arthritis, and ANB032, a BTLA agonist for moderate-to-severe atopic dermatitis. Operations center on advancing these candidates through clinical development.
AnaptysBio's top competitors include Moderna, Roivant Sciences and BeiGene.
AnaptysBio offers Rosnilimab, ANB033, ANB101, Jemperli, and TIM-3 Antagonist.
Yes, AnaptysBio is publicly traded on NASDAQ under the ticker symbol ANAB.
AnaptysBio has 9 investors. Key investors include Frazier Healthcare Partners, BVF Partners, BioMedPartners, LONGWOOD INVESTMENT ADVISORS, and Novo Holdings.
AnaptysBio operates through Anaptysbio, Inc..